https://www.selleckchem.com/pr....oducts/sodium-l-asco
-P13 initiation, or those who had switched from reference infliximab to CT-P13. ClinicalTrials.gov identifiers NCT02557295 (CT-P13 4.2; retrospectively registered on 23 September 2015); NCT02326155 (CT-P13 4.3; retrospectively registered on 25 December 2014); NCT02557308 (CT-P13 4.4; retrospectively registered on 23 September 2015). ClinicalTrials.gov identifiers NCT02557295 (CT-P13 4.2; retrospectively registered on 23 September 2015); NCT02326155 (CT-P13 4.3; retrospectively registered on 25 December 2014); NCT02
Like
Comment
Share
